Koonlawee Nademanee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1503916/publications.pdf Version: 2024-02-01

		30070	16650
127	19,604	54	123
papers	citations	h-index	g-index
133	133	133	8585
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Multisite conduction block in the epicardial substrate of Brugada syndrome. Heart Rhythm, 2022, 19, 417-426.	0.7	20
2	Mechanism of the effects of sodium channel blockade on the arrhythmogenic substrate of Brugada syndrome. Heart Rhythm, 2022, 19, 407-416.	0.7	17
3	Purkinje network and myocardial substrate at the onset of human ventricular fibrillation: implications for catheter ablation. European Heart Journal, 2022, 43, 1234-1247.	2.2	30
4	Dependence of epicardial T-wave on local activation voltage in Brugada syndrome. Heart Rhythm, 2022, 19, 1686-1688.	0.7	5
5	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm, 2021, 18, e1-e50.	0.7	151
6	Genetic risks and association with severe COVID-19 among global populations. Pathogens and Global Health, 2021, 115, 209-210.	2.3	0
7	Role of Catheter Ablation for Ventricular Arrhythmias in Brugada Syndrome. Current Cardiology Reports, 2021, 23, 54.	2.9	6
8	Clinical Characteristics of <i>SCN5A</i> p.R965C Carriers: A Common Founder Variant Predisposing to Brugada Syndrome in Thailand. Circulation Genomic and Precision Medicine, 2021, 14, e003229.	3.6	3
9	Radiofrequency ablation in Brugada syndrome. Heart Rhythm, 2021, 18, 1805-1806.	0.7	9
10	Ablation of Ventricular Arrhythmias Arising From the Pulmonary Artery. JACC: Case Reports, 2021, 3, 1743-1745.	0.6	0
11	Two Faces of Brugada Syndrome. JACC: Clinical Electrophysiology, 2020, 6, 1364-1366.	3.2	3
12	Atrial fibrillation ablation in the 21st century: Almost no stroke risk?. Heart Rhythm, 2020, 17, 2100-2101.	0.7	0
13	Structurally Abnormal Myocardium Underlies Ventricular Fibrillation Storms in a Patient Diagnosed With the EarlyÂRepolarization Pattern. JACC: Clinical Electrophysiology, 2020, 6, 1395-1404.	3.2	15
14	Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation. Scientific Reports, 2020, 10, 18969.	3.3	11
15	Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand. Heart Rhythm, 2020, 17, 2145-2153.	0.7	23
16	Mapping and Ablation of Ventricular Fibrillation Associated With Early Repolarization Syndrome. Circulation, 2019, 140, 1477-1490.	1.6	80
17	Ablation of Genetically Triggered Ventricular Tachycardia/Fibrillation—Focusing on Brugada Syndrome. , 2019, , 619-624.e1.		0
18	Depolarization versus repolarization abnormality underlying inferolateral J-wave syndromes: New concepts in sudden cardiac death with apparently normal hearts. Heart Rhythm, 2019, 16, 781-790.	0.7	52

#	Article	IF	CITATIONS
19	Epicardial ablation utilizing remote magnetic navigation in a patient with Brugada syndrome and inferior early repolarization. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 214-217.	1.2	11
20	Endocardial Ablation Approach for Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006675.	4.8	5
21	Localized Structural Alterations Underlying a Subset of Unexplained Sudden Cardiac Death. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006120.	4.8	67
22	Brugada Syndrome: Current Perspectives. Cardiac and Vascular Biology, 2018, , 187-214.	0.2	0
23	Repolarization Versus Depolarization Defects in Brugada Syndrome. JACC: Clinical Electrophysiology, 2017, 3, 364-366.	3.2	12
24	Epicardial substrate ablation for Brugada syndrome. Heart Rhythm, 2017, 14, 457-461.	0.7	70
25	Ablation of complex fractionated electrograms is useful for catheter ablation of persistent atrial fibrillation: Protagonist point of view. Heart Rhythm, 2016, 13, 2098-2100.	0.7	12
26	Will we be able to cure brugada syndrome?. Heart Rhythm, 2016, 13, 2159-2160.	0.7	7
27	Epicardial Substrate Ablation in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1306-1308.	4.8	14
28	Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm, 2015, 12, 44-51.	0.7	89
29	ST-Segment Elevation and Fractionated Electrograms in Brugada Syndrome Patients Arise From the Same Structurally Abnormal Subepicardial RVOT Area but Have a Different Mechanism. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1382-1392.	4.8	43
30	Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome. Journal of the American College of Cardiology, 2015, 66, 1976-1986.	2.8	315
31	Overlapping Risks ofÂEarly Repolarization and Brugada Syndrome. Journal of the American College of Cardiology, 2014, 63, 2139-2140.	2.8	6
32	Lai Tai, the Mysterious Death of Young Thai Men. , 2014, , 265-277.		0
33	Treatment of electrical storms in Brugada syndrome. Journal of Arrhythmia, 2013, 29, 117-124.	1.2	9
34	Brugada Syndrome. Circulation Journal, 2012, 76, 2713-2722.	1.6	73
35	Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of	1.7	1,497
36	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.7	1,541

#	Article	IF	CITATIONS
37	Exercise and Vagal Reflex in Long QT Syndrome Type 1. Journal of the American College of Cardiology, 2012, 60, 2525-2526.	2.8	3
38	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 171-257.	1.3	1,167
39	Left Atrial Ablation of Atrial Fibrillation: Is the Fly in the Ointment a Silent Stroke?. Journal of Cardiovascular Electrophysiology, 2012, 23, 574-575.	1.7	2
40	Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure. Journal of Cardiac Failure, 2011, 17, 710-717.	1.7	91
41	Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract Epicardium. Circulation, 2011, 123, 1270-1279.	1.6	663
42	Mapping of complex fractionated atrial electrograms as target sites for AF ablation. , 2011, 2011, 5539-42.		4
43	Catheter ablation of atrial fibrillation guided by complex fractionated atrial electrogram mapping of atrial fibrillation substrate. Journal of Cardiology, 2010, 55, 1-12.	1.9	91
44	Pulmonary Vein Isolation Without Reconnection: A Decade of Trying. Journal of Cardiovascular Electrophysiology, 2010, 21, 738-740.	1.7	2
45	KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm, 2010, 7, 199-205.	0.7	26
46	Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm, 2010, 7, 1872-1882.	0.7	387
47	The Role of Complex Fractionated Atrial Electrograms in Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 2009, 53, 790-791.	2.8	27
48	Genotype–Phenotype Relationship in the Long QT Syndrome. Journal of the American College of Cardiology, 2009, 54, 2063-2064.	2.8	1
49	Clinical Outcomes of Catheter Substrate Ablation for High-Risk Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 843-849.	2.8	310
50	Trials and Travails of Electrogram-Guided Ablation of Chronic Atrial Fibrillation. Circulation, 2007, 115, 2592-2594. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:	1.6	30
51	Recommendations for Personnel, Policy, Procedures and Follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS): in collaboration with the American College of Cardiology (ACC). American Heart	1.7	741
52	Association (AHA), and the Soci. Europace, 2007, 9, 335-379. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. Heart Rhythm, 2007, 4, 816-861.	0.7	1,258
53	Percutaneous Epicardial Catheter Ablation Opens Another Chapter in the Catheterâ€Based Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2007, 18, 924-925.	1.7	2
54	How to perform electrogram-guided atrial fibrillation ablation. Heart Rhythm, 2006, 3, 981-984.	0.7	61

#	Article	IF	CITATIONS
55	ls pulmonary vein isolation by segmental ostial ablation a correct approach for treatment of atrial fibrillation?. Heart Rhythm, 2006, 3, 1029-1030.	0.7	3
56	Clinical Experience with Tiered Atrial Therapies and Atrial Arrhythmia Prevention Algorithms in a Dual Chamber Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology, 2006, 17, 852-856.	1.7	5
57	Brugada Syndrome: Report of the Second Consensus Conference. Circulation, 2005, 111, 659-670.	1.6	1,639
58	Brugada Syndrome: Report of the Second Consensus Conference. Heart Rhythm, 2005, 2, 429-440.	0.7	429
59	A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. Journal of the American College of Cardiology, 2004, 43, 2044-2053.	2.8	1,867
60	Heart rate variability in patients with sudden unexpected cardiac arrest in Thailand. American Journal of Cardiology, 2003, 91, 77-81.	1.6	15
61	Defibrillator Versus Î ² -Blockers for Unexplained Death in Thailand (DEBUT). Circulation, 2003, 107, 2221-2226.	1.6	142
62	Heart rate variability in patients with Brugada syndrome in Thailand. European Heart Journal, 2003, 24, 1771-1778.	2.2	52
63	Long-Term Follow-Up of Individuals With the Electrocardiographic Pattern of Right Bundle-Branch Block and ST-Segment Elevation in Precordial Leads V 1 to V 3. Circulation, 2002, 105, 73-78.	1.6	593
64	Proposed Diagnostic Criteria for the Brugada Syndrome. Circulation, 2002, 106, 2514-2519.	1.6	779
65	Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Human Molecular Genetics, 2002, 11, 337-345.	2.9	334
66	Novel mutations in domain I of SCN5A cause Brugada syndrome. Molecular Genetics and Metabolism, 2002, 75, 317-324.	1.1	61
67	Complications in the Implantation of Dual-Chamber ICD. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 107-108.	1.0	2
68	What Is the Sudden Death Syndrome in Southeast Asian Males?. Cardiology in Review, 2000, 8, 90-95.	1.4	11
69	Nonfluoroscopic Three-Dimensional Mapping for Arrhythmia Ablation: Tool or Toy?. Journal of Cardiovascular Electrophysiology, 2000, 11, 239-243.	1.7	56
70	Treating Electrical Storm. Circulation, 2000, 102, 742-747.	1.6	440
71	Initial Clinical Experience with a Fully Automatic In-Hospital External Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1648-1655.	1.2	20
72	Complications of Implantation. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 322-323.	1.0	2

Koonlawee Nademanee

#	Article	IF	CITATIONS
73	A Nonfluoroscopic Catheter-Based Mapping Technique to Ablate Focal Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1442-1447.	1.2	62
74	Long-term antithrombotic treatment for atrial fibrillation. American Journal of Cardiology, 1998, 82, 37N-42N.	1.6	19
75	Arrhythmogenic Marker for the Sudden Unexplained Death Syndrome in Thai Men. Circulation, 1997, 96, 2595-2600.	1.6	443
76	Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy. Journal of the American College of Cardiology, 1996, 28, 1168-1174.	2.8	94
77	Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a mmulticenter trial. American Journal of Cardiology, 1996, 77, 72A-82A.	1.6	47
78	Clinical Significance of a New P Wave Lead Vector for Pacemaker Follow-Up of Atrial Functions. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1805-1808.	1.2	1
79	Effects of Sotalol on His-Purkinje Conduction and Refractoriness in Humans. Journal of Cardiovascular Pharmacology and Therapeutics, 1996, 1, 9-16.	2.0	1
80	Antianginal and Antiischemic Efficacy of Monotherapy Extended-Release Nisoldipine (Coat Core) in Chronic Stable Angina. Journal of Clinical Pharmacology, 1995, 35, 780-784.	2.0	10
81	Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. American Heart Journal, 1995, 130, 1250-1253.	2.7	164
82	Long-Term Efficacy of Amiodarone for the Maintenance of Normal Sinus Rhythm in Patients With Refractory Atrial Fibrillation or Flutter. American Journal of Cardiology, 1995, 76, 47-50.	1.6	237
83	Cardiovascular Effects and Toxicities of Cocaine. Journal of Addictive Diseases, 1992, 11, 71-82.	1.3	18
84	The amiodarone odyssey. Journal of the American College of Cardiology, 1992, 20, 1063-1065.	2.8	15
85	Treatment of catecholamine-sensitive right ventricular tachycardia by endocardial catheter ablation. Journal of the American College of Cardiology, 1990, 16, 752-755.	2.8	12
86	Myocardial Ischemia during Cocaine Withdrawal. Annals of Internal Medicine, 1989, 111, 876.	3.9	129
87	Amiodarone and thyroid function. Progress in Cardiovascular Diseases, 1989, 31, 427-437.	3.1	89
88	The historical development, cellular electrophysiology and pharmacology of amiodarone. Progress in Cardiovascular Diseases, 1989, 31, 249-280.	3.1	109
89	Oral N-acetylprocainamide compared to quinidine plus digoxin in the chronic suppression of atrial flutter in humans. Cardiovascular Drugs and Therapy, 1989, 3, 191-198.	2.6	4
90	Slow conduction in the infarct scar: Relevance to the occurrence, detection, and ablation of ventricular reentry circuits resulting from myocardial infarction. American Heart Journal, 1989, 117, 452-467.	2.7	61

#	Article	IF	CITATIONS
91	Fractionated endocardial electrograms are associated with slow conduction in humans: Evidence from pace-mapping. Journal of the American College of Cardiology, 1989, 13, 369-376.	2.8	116
92	Variability of indexes for myocardial ischemia: A comparison of exercise treadmill test, ambulatory electrocardiographic monitoring and symptoms of myocardial ischemia. Journal of the American College of Cardiology, 1989, 13, 574-579.	2.8	22
93	Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. American Heart Journal, 1988, 115, 102-107.	2.7	24
94	Control of Cardiac Arrhythmias by Calcium Antagonism. Annals of the New York Academy of Sciences, 1988, 522, 536-552.	3.8	21
95	Resetting of ventricular tachycardia: Implications for localizing the area of slow conduction. Journal of the American College of Cardiology, 1988, 11, 522-529.	2.8	90
96	Severity of silent myocardial ischemia on ambulatory electrocardiographic monitoring in patients with stable angina pectoris: Relation to prognostic determinants during exercise stress testing and coronary angiography. Journal of the American College of Cardiology, 1988, 12, 1169-1176.	2.8	56
97	Hemodynamic and Electrophysiologic Effects of Combined Infusion of Lidocaine and Propafenone in Humans. Journal of Clinical Pharmacology, 1987, 27, 52-59.	2.0	4
98	Sotalol: A beta blocker with unique antiarrhythmic properties. American Heart Journal, 1987, 114, 121-139.	2.7	82
99	Antihypertensive compounds as antiarrhythmic agents: Focus on beta-blocking drugs in ventricular arrhythmias. American Heart Journal, 1987, 114, 1040-1050.	2.7	6
100	Prognostic significance of silent myocardial ischemia in patients with unstable angina. Journal of the American College of Cardiology, 1987, 10, 1-9.	2.8	307
101	Abolition of holter monitor-detected silent myocardial ischemia after percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology, 1987, 10, 499-503.	2.8	31
102	Sotalol. Drugs, 1987, 34, 311-349.	10.9	86
103	Circadian variation in occurrence of transient overt and silent myocardial ischemia in chronic stable angina and comparison with prinzmetal angina in men. American Journal of Cardiology, 1987, 60, 494-498.	1.6	131
104	Beta-adrenergic blockade in unstable angina pectoris. American Journal of Cardiology, 1986, 57, 992-994.	1.6	4
105	Amiodarone, thyroid hormone indexes, and altered thyroid function: Long-term serial effects in patients with cardiac arrhythmias. American Journal of Cardiology, 1986, 58, 981-986.	1.6	60
106	Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block. Journal of the American College of Cardiology, 1986, 7, 180-184.	2.8	9
107	Newer Concepts in the Pathogenesis of Myocardial Ischaemia. Drugs, 1986, 32, 1-14.	10.9	11
108	Thyroxine and triiodothyronine kinetics in cardiac patients taking amiodarone. European Journal of Endocrinology, 1986, 111, 193-199.	3.7	41

#	Article	IF	CITATIONS
109	Mexiletine: Double-blind comparison with procainamide in PVC suppression and open-label sequential comparison with amiodarone in life-threatening ventricular arrhythmias. American Heart Journal, 1985, 110, 923-931.	2.7	13
110	Control of cardiac arrhythmias by selective lengthening of repolarization: Theoretic considerations and clinical observations. American Heart Journal, 1985, 109, 421-430.	2.7	129
111	Comparative electrophysiologic profiles of calcium antagonists with particular reference to bepridil. American Journal of Cardiology, 1985, 55, C14-C19.	1.6	40
112	The Electrophysiology and Pharmacology of Verapamil, Flecainide, and Amiodarone: Correlations with Clinical Effects and Antiarrhythmic Actions. Annals of the New York Academy of Sciences, 1984, 432, 210-235.	3.8	11
113	Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes. Journal of the American College of Cardiology, 1984, 3, 1298-1307.	2.8	29
114	Amiodarone-digoxin interaction: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. Journal of the American College of Cardiology, 1984, 4, 111-116.	2.8	103
115	Electrophysiologic effects of amiodarone: Experimental and clinical observation relative to serum and tissue drug concentrations. American Heart Journal, 1984, 108, 890-898.	2.7	109
116	Beta-adrenergic blockade by nadolol in control of ventricular tachyarrhythmias. American Heart Journal, 1984, 108, 1109-1115.	2.7	18
117	Calcium Antagonists Clinical Use in the Treatment of Arrhythmias. Drugs, 1983, 25, 125-153.	10.9	99
118	Amiodarone and thyroid function: Clinical implications during antiarrhythmic therapy. American Heart Journal, 1983, 106, 857-869.	2.7	122
119	Control of sudden recurrent arrhythmic deaths: Role of amiodarone. American Heart Journal, 1983, 106, 895-901.	2.7	28
120	Antiarrhythmic Effects of Verapamil. Angiology, 1983, 34, 572-590.	1.8	3
121	Accurate rapid compact analog method for the quantification of frequency and duration of myocardial ischemia by semiautomated analysis of 24-hour Holter ECG recordings. American Heart Journal, 1982, 103, 802-813.	2.7	39
122	Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: Potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. American Heart Journal, 1982, 103, 950-959.	2.7	180
123	Amiodarone: Possibly an ideal antiarrhythmic agent. American Journal of Cardiology, 1982, 49, 981.	1.6	5
124	Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Progress in Cardiovascular Diseases, 1982, 25, 103-132.	3.1	89
125	Amiodarone kinetics after oral doses. Clinical Pharmacology and Therapeutics, 1982, 31, 438-444.	4.7	135
126	Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. American Heart Journal, 1981, 101, 759-768.	2.7	151

#	Article	IF	CITATIONS
127	Hyperthyroxinemia with Bradycardia and Normal Thyrotropin Secretion after Chronic Amiodarone Administration*. Journal of Clinical Endocrinology and Metabolism, 1981, 53, 997-1001.	3.6	159